Concerning PSA Levels in Elderly Men

Age-Specific PSA Reference Ranges

For men aged 70-79 years, the age-specific reference range for PSA is 0-6.5 ng/mL for white men, 0-5.5 ng/mL for African-American men, and 0-5.0 ng/mL for Asian-American men 1, 2
The median PSA value for men in their 70s is approximately 1.5 ng/mL, which can serve as a baseline reference 1

The NCCN panel uniformly discourages PSA testing in men unlikely to benefit from prostate cancer diagnosis based on age and/or comorbidity 3
Very few men older than 75 years benefit from PSA testing, and routine screening in this population substantially increases rates of overdetection 3, 4
For men aged 75 years or older with a PSA level less than 3.0 ng/mL, evidence suggests they are unlikely to die from or experience aggressive prostate cancer during their remaining lifetime 4, 5

In men over 80 years, approximately 75% or more of cases detected by PSA screening with PSA less than 10 ng/mL and Gleason score 6 or below are overdiagnosed 6, 7
The American Urological Association (AUA) guidelines note that the ratio of harm to benefit increases with age, and the likelihood of overdiagnosis is extremely high in elderly men 7

For an elderly male with PSA <3.0 ng/mL, further testing is not recommended due to very low risk of clinically significant prostate cancer 4, 5
For an elderly male with PSA 3.0-6.5 ng/mL, consideration of further evaluation depends on health status and life expectancy 3, 6, 7
For an elderly male with PSA >6.5-10.0 ng/mL, consideration of PSA velocity and higher risk of clinically significant disease is necessary, but overdiagnosis risk remains high 1, 6
For an elderly male with PSA >10.0 ng/mL, further evaluation may be warranted if the patient is otherwise healthy, due to higher likelihood of clinically significant disease 3, 7

When evaluating PSA in an elderly male, consideration of whether detection and treatment would improve mortality or quality of life given the patient's overall health status and life expectancy is crucial 6, 8
For most men this age, even with elevated PSA, the risks of further investigation often outweigh potential benefits 7
If PSA is >10 ng/mL and the patient is otherwise healthy with good functional status, further evaluation may be warranted to prevent potential morbidity from advanced disease 3, 7

The National Comprehensive Cancer Network recommends estimating life expectancy using validated tools, such as Charlson comorbidity scores, life insurance tables, or geriatric assessment tools, rather than age alone, for men with elevated PSA 9, 10
The National Comprehensive Cancer Network suggests that PSA testing should only be offered to men with at least 10 years of life expectancy, as the benefits of screening are questionable in those with limited life expectancy 9, 11, 12
At age 85, even healthy men typically have limited life expectancy, making screening benefits questionable, according to the National Comprehensive Cancer Network 9

The American Urological Association and the National Comprehensive Cancer Network recommend against proceeding with prostate biopsy if life expectancy is less than 10 years, as the harms of screening outweigh potential benefits 9, 11
The National Comprehensive Cancer Network recommends monitoring for symptoms of urinary obstruction or bone pain that would indicate symptomatic disease requiring palliative intervention, rather than proceeding with aggressive workup, for men with limited life expectancy 9

The American Urological Association recommends assessing for lower urinary tract symptoms using validated questionnaires, such as I-PSS, and performing urinalysis to exclude infection or hematuria from other causes, for men with elevated PSA and limited life expectancy 12, 13
The National Comprehensive Cancer Network suggests reserving imaging and further workup only for symptoms suggesting metastatic disease, such as bone pain or neurologic symptoms, and treating symptomatic urinary obstruction with alpha-blockers or 5-alpha reductase inhibitors for benign prostatic hyperplasia 9, 12

The American College of Oncology suggests that a PSA level greater than 10.0 ng/mL confers a greater than 50% probability of prostate cancer, regardless of age 14
The American College of Oncology recommends that further evaluation may be warranted for men with a PSA level greater than 10.0 ng/mL, if the patient is otherwise healthy with good functional status 14

The American College of Oncology states that symptomatic presentation changes the equation, and if a man over 71 presents with urinary symptoms, PSA measurement is appropriate regardless of screening recommendations 14
The American College of Oncology notes that at age 71, latent subclinical prostate cancer is very common, but only about 10% of latent cancers will eventually become clinical cancers 14